Auxogyn, Inc., a Menlo Park, Calif.-based company advancing women’s reproductive health, has raised $18m in Series B financing.
The round was led by new investor SR One, with participation from Series A investors Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.
The company intends to use the funding to support regulatory clearance and commercial launch of its Early Embryo Viability Assessment, Eeva, a non-invasive test designed to provide objective information regarding the viability of embryos during in vitrofertilization (IVF) procedures.
In conjunction with the financing, Simeon J. George, M.D., partner at SR One, and Nilesh Kumar, Ph.D., director of Merck Serono Ventures, will join Auxogyn’s board of directors.
The company is led by Lissa Goldenstein, President and CEO.